Evidence map›Paper›PMID 36343328›Full record

ArticleJournal of proteome research2022

Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.

Eleonora Forte, Benjamin J Des Soye, Rafael D Melani, Michael A R Hollas, Jared O Kafader, Beverly E Sha, Jeffrey R Schneider, Neil L Kelleher

Open access · greenAbstract read
In one paragraph

Article in Journal of proteome research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Eleonora ForteProteomics Center of Excellence, Evanston, Illinois60208, United States.
Benjamin J Des SoyeProteomics Center of Excellence, Evanston, Illinois60208, United States.ORCID 0000-0001-5480-4192
Rafael D MelaniProteomics Center of Excellence, Evanston, Illinois60208, United States.
Michael A R HollasProteomics Center of Excellence, Evanston, Illinois60208, United States.ORCID 0000-0002-0797-3134
Jared O KafaderProteomics Center of Excellence, Evanston, Illinois60208, United States.ORCID 0000-0002-5359-264X
Beverly E ShaDivision of Infectious Diseases, Rush University Medical Center, Chicago, Illinois60612, United States.ORCID 0000-0002-9659-3554
Jeffrey R SchneiderDepartment of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, Illinois60612, United States.
Neil L KelleherProteomics Center of Excellence, Evanston, Illinois60208, United States.
Abterra Biosciences (United States) · USNorthwestern University · USRush University Medical Center · US

Funding

TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
NIAID NIH HHS HHSN272201400008CNIGMS NIH HHS P41 GM108569
6 · The paper itself

Abstract

SARS-CoV-2 Omicron (B.1.1.529) and its subvariants are currently the most common variants of concern worldwide, featuring numerous mutations in the spike protein and elsewhere that collectively make Omicron variants more transmissible and more resistant to antibody-mediated neutralization provided by vaccination, previous infections, and monoclonal antibody therapies than their predecessors. We recently reported the creation and characterization of Ig-MS, a new mass spectrometry-based serology platform that can define the repertoire of antibodies against an antigen of interest at single proteoform resolution. Here, we applied Ig-MS to investigate the evolution of plasma antibody repertoires against the receptor-binding domain (RBD) of SARS-CoV-2 in response to the booster shot and natural viral infection. We also assessed the capacity for antibody repertoires generated in response to vaccination and/or infection with the Omicron variant to bind to both Wuhan- and Omicron-RBDs. Our results show that (1) the booster increases antibody titers against both Wuhan- and Omicron- RBDs and elicits an Omicron-specific response and (2) vaccination and infection act synergistically in generating anti-RBD antibody repertoires able to bind both Wuhan- and Omicron-RBDs with variant-specific antibodies.

Indexed as

COVID-19SARS-CoV-2AntibodiesAntibodies, ViralHumansImmunotherapyAntibodiesAntibodies, ViralantibodiesCOVID-19Ig-MSOmicron variantSARS-CoV-2serology

Identifiers

PMID36343328
PMCPMC9668041
OpenAlexW4308374961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.